INSMED INC Unrealized Gain (Loss) on Derivatives
INSMED INC (INSM) reported Unrealized Gain (Loss) on Derivatives of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2026-02-19
- INSMED INC unrealized gain (loss) on derivatives for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC unrealized gain (loss) on derivatives for the quarter ending 2025-09-30 was $0.00.
- INSMED INC unrealized gain (loss) on derivatives for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- INSMED INC unrealized gain (loss) on derivatives for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC unrealized gain (loss) on derivatives for fiscal 2025 was $0.00.
- INSMED INC unrealized gain (loss) on derivatives for fiscal 2024 was -$236.00K, a 173.75% decline from fiscal 2023.
- INSMED INC unrealized gain (loss) on derivatives for fiscal 2023 was $320.00K.
- INSMED INC unrealized gain (loss) on derivatives for fiscal 2022 was -$1.53M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | $870.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $870.00K derived: sum of 3 quarters · filed 2026-02-19 | -$2.98M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $870.00K derived: sum of 2 quarters · filed 2026-02-19 | -$2.98M derived: sum of 3 quarters · filed 2026-02-19 | -$2.60M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-12-31 | $870.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$2.98M derived: sum of 2 quarters · filed 2026-02-19 | -$2.60M derived: sum of 3 quarters · filed 2026-02-19 | -$236.00K 10-K · filed 2026-02-19 |
| 2024-09-30 | -$3.85M 10-Q · filed 2025-10-30 | -$3.47M derived: sum of 2 quarters · filed 2025-10-30 | -$1.11M 10-Q · filed 2025-10-30 | $864.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $384.00K 10-Q · filed 2025-08-07 | $2.75M 10-Q · filed 2025-08-07 | $4.72M derived: sum of 3 quarters · filed 2026-02-19 | $3.42M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $2.36M 10-Q · filed 2025-05-08 | $4.33M derived: sum of 2 quarters · filed 2026-02-19 | $3.03M derived: sum of 3 quarters · filed 2026-02-19 | $4.21M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $669.00K derived: sum of 2 quarters · filed 2026-02-19 | $1.85M derived: sum of 3 quarters · filed 2026-02-19 | $320.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | -$1.30M 10-Q · filed 2024-10-31 | -$117.00K derived: sum of 2 quarters · filed 2024-10-31 | -$1.65M 10-Q · filed 2024-10-31 | -$3.18M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $1.18M 10-Q · filed 2024-08-08 | -$349.00K 10-Q · filed 2024-08-08 | -$1.88M derived: sum of 3 quarters · filed 2025-02-20 | -$1.88M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$1.53M 10-Q · filed 2024-05-09 | -$3.06M derived: sum of 2 quarters · filed 2025-02-20 | -$3.06M derived: sum of 3 quarters · filed 2025-02-20 | -$3.06M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | -$1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$1.53M derived: sum of 2 quarters · filed 2025-02-20 | -$1.53M derived: sum of 3 quarters · filed 2025-02-20 | -$1.53M 10-K · filed 2025-02-20 |
| 2022-09-30 | $0.00 10-Q · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $0.00 10-Q · filed 2023-10-26 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |